Tweets
Upadacitinib RA program (5306 pts) the risk of H. zoster by Rx and dose (HZ/100PYs)
MTX = 0.8/100PY
ADA+MTX= 1.1/100PY
UPA 15 mg= 3.0/100PY
UPA 30 mg = 5.3/100PY
Hence there is a 4-5X risk of HZ w/ JAKinhibitors
https://t.co/wo9ih5PJ77 https://t.co/Zv9sSRBSHb
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Having both Cancer & Systemic sclerosis (SSc) is rare. Study of 1481 SSc pts saw cancer Dx w/in 2, (1.35), 3 (2.1%) & 5 yrs (3.5%;mostly breast, GYN, Heme CA). Higher 2 yr risk w/ topoisomerase I Ab (OR 3.43), U1-RNP (5.54), but not RNA polymerase III) https://t.co/dVuchv8Afv https://t.co/azGmJYifrj
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Study of 52 pts with Juvenile Systemic Sclerosis (JSSc) -10% were without skin dz (SSc sine scleroderma). 7 pts reviewed, all had cardiac dz (86 vs 16%; 3 cardiomyopathy, 3PAH), longer Dx delay (20 vs 8 mos), worse outcomes, (42 v 6%) https://t.co/7wGuX8QVBO https://t.co/XdTK7AlPrs
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
MEDWATCH (FAERS) data on venous thromboembolic (VTE) risk with JAK inhibitors from 2010-2019 https://t.co/oKkTYcRsxL
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
“Hiker’s feet” newly proposed cutaneous foot manifestations of dermatomyositis. Most pts had the antisynthetase syndrome (with anti-Jo-1) and almost all had mechanic’s hands. Such findings should prompt a search for ILD https://t.co/98EAQUHJbz https://t.co/mJ467Nfe8T
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Hip fractures represent a major global public health problem - data from ASBMR meeting suggests this is from an aging population and suboptimal OP treatment. Global study shows incr # hip fractures per year, but Post-fracture Rx only at 11-50% https://t.co/LlMDTrH93E https://t.co/ucrPzcnLZh
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
2125 RA pts in RCTS w/ baricitinib entered a long term F/U study. baricitinib pts had less XRay damage over 5 yrs; 5 yr No Xray progression was 60% on baricitinib 4 mg; 66% baricitinib 4 mg+MTX; vs 41% on just MTX monotherapy. https://t.co/pLuQCDSf6g https://t.co/wFs3G0DrJ7
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
SLE hospitalized with ARDS from COVID-19 have significantly higher risks of death and poor outcomes (RR=1.7), compared 319 SLE vs 251,800 nonSLE - SLE was more impactful than other comorbidities in such poor outcomes https://t.co/8VJjdOmTbi https://t.co/jYTg6k1QNq
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
We are at that time of year when rheumatology fellowship programs across the nation are exploring potential candidates to train. We share tips for both the interviewer and candidates on the blog today.
https://t.co/eWQs9CwqSm https://t.co/iHeuQpsoQx
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Lessebo effect: 31 RCT comparing Biologic originator to a biosimilar or to PBO: Lessebo effx =better responses in Biosimilar vs PBO (ACR20=70%) than w/ originator vs PBO (ACR20=59%). ? due to PBO effx in active comparator, nocebo in PBO trials https://t.co/kvANomTHrb
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Beliefs translate to effects - ‘it will work’ (Placebo), ‘it will hurt’ (Nocebo); but now a "Lessebo" effect; neither benefit nor harm; instead a lower effect based on comparator. TNFi vs PBO has smaller effx (sup trial) than Biosimilar vs PBO (equiv) https://t.co/onyIkILqT9
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Drug Safety Risk Communication- The 800 lb Gorilla Approach
https://t.co/6iSJjvlFF8 https://t.co/mPeJfWi1hY
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
